Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Akebia Therapeutics (AKBA) Amortization of Deferred Charges (2019 - 2020)

Akebia Therapeutics has reported Amortization of Deferred Charges over the past 2 years, most recently at -$647000.0 for Q1 2020.

Quarterly Amortization of Deferred Charges fell 5.37% to -$647000.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$2.3 million through Mar 2020, changed N/A year-over-year, with the annual reading at -$2.2 million for FY2019, N/A changed from the prior year.
Amortization of Deferred Charges was -$647000.0 for Q1 2020 at Akebia Therapeutics, down from -$556000.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at -$483000.0 in Q2 2019 and troughed at -$647000.0 in Q1 2020.